Hirsutism in Women: A Comprehensive Clinical Overview

Abstract

Hirsutism, defined as the presence of coarse, dark terminal hair in a male pattern distribution in women, represents one of the most common manifestations of hyperandrogenism. While often an isolated cosmetic concern, hirsutism may signal significant underlying endocrine pathology, including polycystic ovary syndrome (PCOS), adrenal or ovarian tumors, and nonclassic congenital adrenal hyperplasia. This article provides a comprehensive review of the definition, epidemiology, pathogenesis, etiology, diagnostic evaluation, and evidence-based treatment modalities for hirsutism, drawing upon established clinical guidelines and research findings.

1. Definition and Clinical Assessment

Hirsutism is clinically defined as the presence of thick, stiff, pigmented terminal hairs in a male pattern distribution—typically affecting the upper lip, chin, sideburns, chest, abdomen, and back—in women. The condition must be evaluated within the context of cultural, ethnic, and racial norms; for instance, women of Mediterranean descent naturally possess greater terminal hair density compared to Asian or Native American women.

The Ferriman-Gallwey scoring system serves as the gold standard for clinical assessment. Each of 11 designated body areas is graded from 0 (absence of terminal hair) to 4 (extensive growth), yielding a maximum score of 44. A score greater than 8 is diagnostic of hirsutism, though scores above 10 are found in only 1% of women.

Hirsutism must be distinguished from hypertrichosis, a generalized increase in body hair including areas where terminal hair is not normally found (e.g., forehead). Hypertrichosis is frequently drug-induced (phenytoin, minoxidil, cyclosporine) or associated with systemic diseases such as hypothyroidism, malnutrition, and porphyria.

2. Epidemiology

Population-based studies indicate that approximately 4% of women meet diagnostic criteria for hirsutism (Ferriman-Gallwey score > 8), while only 1% exceed a score of 10. Self-reported prevalence rates are higher; a Finnish cohort study found that 10% of women reported hirsutism, with 2.5% experiencing concurrent oligomenorrhea suggestive of PCOS. Notably, while PCOS is less prevalent than hirsutism in the general population, women with PCOS are overrepresented in endocrine specialty practices due to greater healthcare-seeking behavior.

3. Pathogenesis

The pathophysiology of hirsutism centers on excess androgen production, enhanced androgen action, or both. Androgen overproduction may originate from three sources:

·        Adrenal gland: Produces dehydroepiandrosterone sulfate (DHEAS), DHEA, and androstenedione

·        Ovary: Produces androstenedione and testosterone

·        Hair follicle (pilosebaceous unit): Converts weaker androgens to potent dihydrotestosterone (DHT) via 5-α-reductase type 2

DHT and testosterone represent the most potent human androgens, binding with high affinity to androgen receptors to stimulate terminal hair growth in androgen-sensitive areas while paradoxically promoting scalp hair loss.

Multiple hormonal defects contribute to hirsutism:

1.     Increased pituitary LH secretion → ovarian androgen overproduction

2.     Hyperinsulinemia/insulin resistance → decreased SHBG synthesis → elevated free testosterone

3.     Adrenal enzyme defects → increased androgen-to-cortisol ratio

4.     Enhanced 5-α-reductase activity in hair follicles → increased local DHT conversion

4. Etiology

The differential diagnosis of hirsutism encompasses a spectrum from benign to potentially life-threatening conditions:

Table

4.1 Idiopathic Hirsutism

Defined as hirsutism in women with regular ovulatory menses and no identifiable endocrine disorder. It may represent a mild form of PCOS with androgen levels sufficient to cause hirsutism but insufficient to disrupt ovulation.

4.2 Polycystic Ovary Syndrome (PCOS)

The combination of oligomenorrhea and hyperandrogenism. PCOS accounts for approximately 30% of cases in hirsutism referral populations and carries associations with infertility, endometrial hyperplasia, and type 2 diabetes mellitus.

4.3 Serious Underlying Disease

Approximately 2% of women presenting with hirsutism have serious pathology, including congenital adrenal hyperplasia, ovarian or adrenal tumors, prolactinoma, and acromegaly. Virilization—manifested by frontal balding, clitoromegaly, increased muscle mass, and voice deepening—strongly suggests an androgen-secreting tumor and mandates urgent investigation.

5. Diagnostic Evaluation

5.1 Clinical Features

The menstrual history provides critical diagnostic differentiation:

·        Idiopathic hirsutism: Normal cycles (23–35 days)

·        PCOS: Oligomenorrhea (cycles > 35 days; often < 6 spontaneous cycles/year)

·        Virilizing tumors: Recent onset, rapid progression, amenorrhea

5.2 Laboratory Testing

Recommended initial investigations include:

·        Serum testosterone (total or free): Levels > 150 ng/dL strongly suggest virilizing tumors and warrant endocrinology referral

·        17-hydroxyprogesterone (follicular phase, 8 AM): Elevated levels (> 4 ng/mL) indicate nonclassic congenital adrenal hyperplasia; screening is particularly warranted in high-prevalence ethnic groups (Ashkenazi Jews, Inuits)

·        Serum prolactin: If amenorrhea is present

·        Glucose screening: For obese patients or those with acanthosis nigricans

6. Treatment

Treatment goals include: (1) excluding serious underlying disease; (2) slowing or arresting new hair growth; (3) removing existing hair; (4) managing associated hormonal dysfunction; and (5) addressing long-term metabolic risks.

6.1 Weight Loss

For women with BMI > 27 kg/m², structured weight loss programs (10–20 kg reduction) significantly decrease insulin levels, improve testosterone profiles, and restore ovulation. This represents a foundational intervention in overweight patients.

6.2 Hormonal Therapy

Estrogen-Progestin Contraceptives

Combination oral contraceptives suppress pituitary LH secretion (reducing ovarian androgen production) and increase hepatic SHBG synthesis (decreasing free testosterone). Benefits continue to accrue over 5 years of treatment. Progestin selection matters: less androgenic progestins (drospirenone, desogestrel, norgestimate) are preferred over androgenic formulations (norgestrel, levonorgestrel).

Antiandrogens

·        Spironolactone (50–200 mg/day; typical 100 mg): Most widely used; inhibits androgen receptor binding. ~70% of patients report improvement, with effects peaking at 6 months.

·        Finasteride (5 mg/day): Inhibits 5-α-reductase types 1 and 2. Carries FDA black-box warning regarding teratogenicity in male fetuses.

·        Flutamide (62.5–500 mg/day): Potent androgen receptor antagonist; limited by risk of fatal hepatotoxicity.

·        Ketoconazole (300 mg/day): Effective but poorly tolerated due to gastrointestinal and hepatic side effects.

Combination therapy (oral contraceptive + antiandrogen) may yield superior outcomes compared to monotherapy.

Metformin

At 1,500–2,000 mg/day, metformin improves insulin sensitivity, reduces circulating insulin and testosterone, and decreases Ferriman-Gallwey scores by approximately 25% over 12 months.

GnRH Analogues

Effective in suppressing ovarian androgen production but generally inferior to antiandrogens in efficacy and more expensive; reserved for refractory cases.

6.3 Nonhormonal Approaches

Table

7. Prognosis and Patient Counseling

Patients must be counseled that:

·        Onset of benefit: 3–6 months minimum; hair follicles have a 6-month life cycle

·        First observable change: Hair becomes thinner and lighter before growth rate decreases

·        Recurrence: Discontinuation of hormonal therapy typically results in recurrence within 3–9 months

·        Long-term management: Therapy is generally continued indefinitely, as androgen excess often persists into the late fourth decade

8. Conclusion

Hirsutism represents a common yet clinically significant condition requiring systematic evaluation to distinguish benign causes (idiopathic hirsutism, PCOS) from rare but serious pathology (androgen-secreting tumors). A multimodal treatment approach combining hormonal suppression with mechanical or laser hair removal offers the optimal therapeutic outcome. Long-term management requires attention to metabolic comorbidities, particularly in patients with PCOS, and realistic patient counseling regarding treatment timelines and expectations.

References

1.     Ferriman D, Gallwey JD. Clinical assessment of body hair growth in women. J Clin Endocrinol Metab. 1961;21:1440.

2.     Knochenhauer ES, Key TJ, Kahsar-Miller M, et al. Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States. J Clin Endocrinol Metab. 1998;37:615.

3.     Darendeliler F, Bas F, Balaban S, et al. Spironolactone therapy in hypertrichosis. Eur J Endocrinol. 1996;135:604.

4.     Taponen S, Martikainen H, Jarvelin MR, et al. Hormonal profile of women with self-reported symptoms of oligomenorrhea and/or hirsutism: Northern Finland Birth Cohort 1966 study. J Clin Endocrinol Metab. 2003;88:141.

5.     Kirschner MA, Samojlik E, Silber D. A comparison of androgen production and clearance in hirsute and obese women. J Steroid Biochem. 1983;19:607.

6.     Matteri RK, Stanczyk FZ, Gentzschein EE, et al. Androgen sulfate and glucuronide conjugates in nonhirsute and hirsute women with the polycystic ovary syndrome. Am J Obstet Gynecol. 1992;167:1807.

7.     Samojilk E, Kirschner MA, Silder D, et al. Elevated production and metabolic clearance rates of androgens in morbidly obese women. J Clin Endocrinol Metab. 1984;59:949.

8.     Escobar-Morreale HF, Serrano-Gotarredona J, Garcia-Robles R, et al. Mild adrenal and ovarian steroidogenic abnormalities in hirsute women without hyperandrogenemia: does idiopathic hirsutism exist? Metabolism. 1997;46:902.

9.     Carmina E, Lobo RA. Polycystic ovaries in hirsute women with normal menses. Am J Med. 2001;111:602.

10.  O'Driscoll JB, Mamtora H, Higginson J, et al. A prospective study of the prevalence of clear cut endocrine disorders and polycystic ovaries in 350 women presenting with hirsutism or androgenic alopecia. Clin Endocrinol. 1994;41:231.

11.  Belisle S, Menard J. Adrenal androgen production in hyperprolactinemic states. Fertil Steril. 1980;33:396.

12.  Parker LN, Chang S, Odell WD. Adrenal androgens in patients with chronic marked elevation of prolactin. Clin Endocrinol. 1978;8:1.

13.  Schiebinger RJ, Chrousos GP, Cutler GB Jr, et al. The effect of serum prolactin on plasma adrenal androgens and the production and metabolic clearance rate of dehydroepiandrosterone sulfate in normal and hyperprolactinemic subjects. J Clin Endocrinol Metab. 1986;62:202.

14.  Friedman CI, Schmidt GE, Kim MH, et al. Serum testosterone concentrations in the evaluation of androgen-producing tumors. Am J Obstet Gynecol. 1985;153:44.